Cytokinetics Opens BENEFIT-ALS, A 400 Patient, Phase IIb Clinical…
BENEFIT-ALS Will Evaluate Longer Term Effects of Novel Skeletal Muscle Activator
and Represents a Key Step Forward Towards Potential Registration
(PRWeb October 29, 2012)
Read the full story at http://www.prweb.com/releases/2012/10/prweb10069735.htmClick here for reuse options!
Copyright 2012 Biotechblog
Comments are closed.